Olivier Litzka - Apr 27, 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director
Signature
/s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Apr 27, 2023
Transactions value $
$0
Form type
4
Date filed
5/1/2023, 04:06 PM
Previous filing
Feb 9, 2023
Next filing
May 23, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Other $0 -44K -100% $0.00* 0 Apr 27, 2023 Common Stock 44K $16.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and BioDiscovery 6 FCPI.
F2 The stock option vests in 36 monthly installments beginning on March 9, 2023.